Mersana Therapeutics GAAP EPS of -$4.87 misses by $0.80, revenue of $3.06M misses by $3M

1 hour ago 1

Mersana Therapeutics press release (NASDAQ:MRSN): Q2 GAAP EPS of -$4.87 misses by $0.80.
Revenue of $3.06M (+33.0% Y/Y) misses by $3M.
Net cash used in operating activities for the second quarter of 2025 was $22.6 million, which included $2.4 million in severance-related payments.
Cash and cash equivalents as of June 30, 2025 were $77.0 million.

Recommended For You